<DOC>
	<DOCNO>NCT01187043</DOCNO>
	<brief_summary>The purpose study determine effect five different dos Proellex menses , ovulation , liver function , steady state exposure woman reproductive age .</brief_summary>
	<brief_title>Determination Lowest , Safe Effective Dose Proellex</brief_title>
	<detailed_description>A phase I/II , 5 arm , single blind study , compare five dos Proellex match placebo healthy adult female subject reproductive age . Exposure study drug 10 week . In-clinic pharmacokinetic ( PK ) assessment make first day dose last day ( week 10 ) . Office visit occur every week ass liver function trough blood concentration Proellex primary metabolite . Daily vaginal bleeding diary maintain course study . A single blind run-in period 56 day begin study assess baseline menstrual pattern utilize . Twelve subject per treatment group ( total 60 subject ) assign dose . New group begin dose previous dose group complete . Daily treatment either 1 mg , 3 mg , 6 mg , 9 mg , 12 mg Proellex . A single blind run-in period use placebo incorporate establish baseline parameter .</detailed_description>
	<mesh_term>Amenorrhea</mesh_term>
	<criteria>Ability understand provide write informed consent . Healthy adult females 18 50 year age . Included group woman follow condition , currently receive drug treatment : Excessive menstrual bleeding ; Menstrual pain ; Confirmed uterine fibroid ; Confirmed endometriosis Normal menstrual cycle 2632 day Agree attempt become pregnant Agree limit alcohol consumption 2 drink per week avoid alcohol consumption within 48 hour visit Ability swallow gelatin capsule Ability complete daily subject diary Willing discontinue hormonal contraceptive consent use double barrier contraceptive technique course study . Has negative pregnancy test Screening Baseline visit An exception pregnancy test requirement grant subject report surgical sterilization medical history A Body Mass Index ( BMI ) 18 39 inclusive Is available treatment followup visit Subject postmenopausal woman , define either ; six ( 6 ) month ( immediately prior screen visit ) without menstrual period , prior hysterectomy and/or oophorectomy Subject pregnant lactating attempt expect become pregnant 7 month study period Women abnormal liver enzymes liver disease . Subject previously participate Proellex clinical trial : ZPE201 , ZPU003 , ZPU301 , ZPU302 , ZPU303 , ZPU304 , ZPU305 , ZPU307 . Received investigational drug 30 day prior screen study Women history PCOS Concurrent use testosterone , progestin , androgen , estrogen , anabolic steroid , DHEA hormonal product least 2 week prior screen study . Use oral contraceptive hormone release IUDs precede 30 day . Use DepoProveraÂ® precede 6 month . Women currently use narcotic Women currently take cimetidine spironolactone Clinically significant abnormal finding screen examination condition opinion investigator would interfere participant 's ability comply study instruction endanger participant take part study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Liver Function</keyword>
	<keyword>Steady State Exposure</keyword>
</DOC>